Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
Hui ChangYa-Lan TaoWu JiangChen ChenShi-Liang LiuWei-Jun YeYuan-Hong GaoPublished in: BMC cancer (2020)
For LARC patients treated with insufficient TCC (≤ 7), oxaliplatin of ≥460 mg/m2 might be needed to improve survival, though it might resulted in more acute toxicities.
Keyphrases
- rectal cancer
- locally advanced
- minimally invasive
- liver failure
- coronary artery bypass
- respiratory failure
- drug induced
- aortic dissection
- surgical site infection
- free survival
- coronary artery disease
- lymph node
- intensive care unit
- mechanical ventilation
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome